Yoichiro Kino
Overview
Explore the profile of Yoichiro Kino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ohno M, Sagata M, Sekiya T, Nomura N, Shingai M, Endo M, et al.
Vaccine
. 2022 Dec;
41(3):787-794.
PMID: 36526501
Among inactivated influenza vaccines, the whole virus particle vaccine (WPV) elicits superior priming responses to split virus vaccine (SV) in efficiently inducing humoral and cellular immunity. However, there is concern...
2.
Okada K, Miyazaki C, Kino Y, Ozaki T, Hirose M, Ueda K
J Infect Dis
. 2021 Sep;
224(8):1446-1448.
PMID: 34551107
No abstract available.
3.
Shingai M, Nomura N, Sekiya T, Ohno M, Fujikura D, Handabile C, et al.
Vaccine
. 2021 Jun;
39(29):3940-3951.
PMID: 34090697
Current detergent or ether-disrupted split vaccines (SVs) for influenza do not always induce adequate immune responses, especially in young children. This contrasts with the whole virus particle vaccines (WPVs) originally...
4.
Koutsakos M, Sekiya T, Chua B, Nguyen T, Wheatley A, Juno J, et al.
Immunol Cell Biol
. 2020 Aug;
99(1):97-106.
PMID: 32741011
Influenza remains a significant global public health burden, despite substantial annual vaccination efforts against circulating virus strains. As a result, novel vaccine approaches are needed to generate long-lasting and universal...
5.
Endo M, Tanishima M, Ibaragi K, Hayashida K, Fukuda T, Tanabe T, et al.
Influenza Other Respir Viruses
. 2020 Jun;
14(5):551-563.
PMID: 32579785
Background: We have developed an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66 cell culture platform (KD-295). Objectives: In accordance with Japanese guidelines for development of pandemic prototype vaccines, the...
6.
Sekiya T, Mifsud E, Ohno M, Nomura N, Sasada M, Fujikura D, et al.
Vaccine
. 2019 Mar;
37(15):2158-2166.
PMID: 30857932
In contrast to current ether- or detergent-disrupted "split" vaccines (SVs) for influenza, inactivated whole influenza virus particle vaccines (WPVs) retain the original virus structure and components and as such may...
7.
Yoshikawa T, Ihara T, Watanabe M, Nishimura N, Kino Y
Vaccine
. 2016 Jun;
34(34):4079-82.
PMID: 27317454
No abstract available.
8.
Naruse T, Fukuda T, Tanabe T, Ichikawa M, Oda Y, Tochihara S, et al.
Vaccine
. 2015 Sep;
33(45):6078-84.
PMID: 26409141
Background: We conducted a phase I clinical trial of a cell culture-derived AS03-adjuvanted influenza vaccine containing HA antigen (A/Indonesia/05/2005(H5N1)/PR8-IBCDC-RG2) derived from EB66 cells (KD-295). Methods: Healthy male adult volunteers (20-40...
9.
Nagao M, Fujisawa T, Ihara T, Kino Y
J Allergy Clin Immunol
. 2015 Sep;
137(3):861-7.
PMID: 26365388
Background: Influenza vaccines produced in embryonated eggs might pose a risk to patients with egg allergy. However, patients experiencing influenza vaccine-associated anaphylaxis (IVA) do not always have egg allergy. In...
10.
Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, et al.
Microbiol Immunol
. 2015 Aug;
59(10):597-604.
PMID: 26272602
Two antigenically distinct B strain lineages of influenza virus have co-circulated since the mid-1980s; however, inactivated trivalent influenza vaccines contain only one B lineage. The mismatch between the circulating and...